Deutscher Platz 5a
04103 Leipzig, de
+49 (69) 905505-56
VITA 34 International AG: Clear plus in revenue and EBIT in the first nine months of 2010
- EBIT rises from 0.1m Euro to 0.4m Euro
- Storages of 8,293 above last year's level of 8,105
- Revenue increased by almost eight percent to 12.0m Euro
- Total annual forecast confirmed
The VITA 34 International AG (ISIN DE000A0BL849), parent company of the largest private umbilical cord blood bank in the German-speaking countries, VITA 34 AG, has successfully continued its growth strategy in the first nine months of 2010. Cost reduction measures and the development of business in Spain among other things have led to an improvement of the earnings before interest and taxes (EBIT) to approximately 0.4m Euro, compared to 0.1m Euro for the same period in the previous year. The sales revenues climbed from 11.1m Euro to 12.0m Euro. The number of storages of umbilical cord blood of 8,293 exceeded last year's high level of 8,105.
The corporate result of 0.2m Euro in the period under review in 2010 was slightly lower than the 0.4m Euro in the same period of the previous year, which included a special item from the discontinued operations though. The equity capital increased to 18.8m Euro as per September 30, 2010, compared to 18.6m Euro as per September 30, 2009. Within the scope of the takeover of Secuvita in May 2010, the liquid assets decreased to 4.7m Euro as per the end of September 2010, compared to 7.7m Euro the year before.
As regards the total year 2010, VITA 34 continues to be on target to distinctly improving the profitability and increasing the revenue to 17 to 18m Euro from about 15m Euro in the business year 2009. The successful foreign business is to contribute a considerable share to these goals.
The complete nine months report is available for download at www.vita34group.com.
Die Nutzung von hier veröffentlichten Informationen zur Eigeninformation und redaktionellen Weiterverarbeitung ist in der Regel kostenfrei. Bitte klären Sie vor einer Weiterverwendung urheberrechtliche Fragen mit dem angegebenen Herausgeber. Bei Veröffentlichung senden Sie bitte ein Belegexemplar an email@example.com.